4D pharma will present preclinical data on its rheumatoid arthritis programme at the Keystone Symposium: Microbiome in Health and Disease meeting from February 5 - 9 in Keystone, Colorado. The company will present a poster on its lead candidate, MRx0006, a single-strain live biotherapeutic under investigation for the treatment of rheumatoid arthritis.

The data presented are:

Immunomodulatory effects of a commensal gut microbe alleviate inflammatory responses in an animal model of severe asthma through reduction of neutrophil infiltration in the lung, presented by Emma Raftis, PhD, 4D Pharma Research.

Download PDF